Brooklyn, New York, June 20, 2023 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Breast Cancer Immunotherapy Market is projected to grow at a CAGR of 15.5% from 2023 to 2028.
The market growth of immunotherapy for breast cancer treatment is fueled by the increasing acceptance and utilization of immunotherapy by healthcare professionals. Factors such as the escalating global prevalence of breast cancer, growing awareness of the advantages of immunotherapy in breast cancer treatment, and the significant emphasis of market players on research and development activities further drive the breast cancer immunotherapy market.
Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and in-depth TOC on “Global Breast Cancer Immunotherapy Market - Forecast to 2028’’
Key Market Insights
- As per the treatment type outlook, the monoclonal antibodies segment is expected to be the largest segment in the global breast cancer immunotherapy market from 2023 to 2028.
- As per the end user outlook, the hospitals segment is expected to be the largest segment in the global breast cancer immunotherapy market from 2023 to 2028.
- The Asia Pacific region is analyzed to be the fastest-growing segment in the market.
- North America will have the largest share in the market during the forecast period of 2023-2028.
- Roche, Genentech, Amgen, Antibody Therapeutics, Pfizer, Merck, Novartis, Bristol-Myers, Squibb, EirGenix, and Prestige BioPharma, among others, are some of the key players in the global breast cancer immunotherapy market.
Request for a sample copy of the report @ https://www.globalmarketestimates.com/market-report/breast-cancer-immunotherapy-market-4027
Treatment Type Outlook (Revenue, USD Billion, 2023-2028)
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- Cancer Vaccines
- CAR-T Cell Therapy
End User Outlook (Revenue, USD Billion, 2023-2028)
- Hospitals
- Cancer Research Centers
- Retail Pharmacies
By Regional Outlook (Revenue, USD Billion, 2023-2028)
North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Netherlands
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Thailand
- Indonesia
- Malaysia
- Singapore
- Vietnam
- Rest of APAC
Central & South America
- Brazil
- Argentina
- Chile
- Rest of CSA
Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of MEA
Contact: Yash Jain
Director - Global Accounts & Strategic Advisory
Email address: yash.jain@globalmarketestimates.com
Phone Number: +1 6026667238
Website: www.globalmarketestimates.com
